Current Report Filing (8-k)
October 18 2017 - 6:04AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
October 18, 2017
PROVECTUS
BIOPHARMACEUTICALS, INC.
(Exact
name of registrant as specified in charter)
Delaware
|
|
001-36457
|
|
90-0031917
|
(State or other jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
10025
Investment Drive, Suite 250, Knoxville, TN 37932
(Address
of Principal Executive Offices)
(866)
594-5999
(Registrant’s
Telephone Number, Including Area
Code)
(Former
name or former address, if changed since last
report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not
to use the extended transition
period for complying with any new or revised financial accounting
standards
provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
7.01.
|
Regulation
FD Disclosure.
|
On
October 18, 2017, Provectus Biopharmaceuticals, Inc. (the “Company”) issued a press release (the “Press Release”)
announcing preliminary results from its phase 1b/2 study of the Company’s drug candidate, intralesional PV-10, in combination
with KEYTRUDA® (pembrolizumab), Merck’s systemic anti-PD-1 (programmed death receptor-1) antibody agent, for the treatment
of melanoma. A copy of the Press Release is attached to this Current Report as Exhibit 99.1 and is incorporated herein by reference.
Pursuant
to the rules and regulations of the Commission, the information in this Item 7.01 disclosure, including Exhibit 99.1 and information
set forth therein, is deemed to have been furnished and shall not be deemed to be “filed” under the Securities Exchange
Act of 1934, as amended.
Item
9.01.
|
Financial
Statements and Exhibits.
|
(d)
Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date:
October 18, 2017
|
PROVECTUS BIOPHARMACEUTICALS,
INC.
|
|
|
|
|
By:
|
/s/
Timothy C. Scott
|
|
|
Timothy C. Scott
|
|
|
President
|
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Sep 2023 to Sep 2024